Literature DB >> 21925952

Chronic non-bacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression.

S R Hofmann1, T Schwarz, J C Möller, H Morbach, A Schnabel, A Rösen-Wolff, H J Girschick, C M Hedrich.   

Abstract

Chronic non-bacterial osteomyelitis (CNO) is an auto-inflammatory disorder that affects the skeletal system. Interleukin (IL-)10 is an immune-modulatory cytokine that controls inflammation, and limits inflammatory cytokine responses. Dysregulation of IL-10 expression has been shown to result in autoimmune and infectious diseases. We investigated IL-10 expression by monocytic cells from CNO patients and controls. In response to stimulation with LPS, IL-10 expression from CNO monocytes was reduced (p<0.001). This was independent of IL10 promoter polymorphisms. Thus, we investigated Sp1 recruitment to the IL10 promoter and saw markedly reduced binding in CNO monocytes. This was accompanied with reduced phosphorylation of histone H3 serine 10 (H3S10), an activating epigenetic mark. Impaired recruitment of Sp1 to the IL10 promoter, and reduced H3S10 phosphorylation, may be a reflection of deficient MAPK signaling in CNO monocytes in response to LPS stimulation. Thus, we have discovered a mechanism that may be central in the pathophysiology of CNO.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21925952     DOI: 10.1016/j.clim.2011.08.012

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  37 in total

1.  Unexpectedly high incidences of chronic non-bacterial as compared to bacterial osteomyelitis in children.

Authors:  A Schnabel; U Range; G Hahn; T Siepmann; R Berner; C M Hedrich
Journal:  Rheumatol Int       Date:  2016-10-11       Impact factor: 2.631

2.  Endodontic Infection-induced Inflammation Resembling Osteomyelitis of the Jaws in Toll-like Receptor 2/Interleukin 10 Double-knockout Mice.

Authors:  Hajime Sasaki; Hisako Furusho; Daniel B Rider; Justine M Dobeck; Winston Patrick Kuo; Akira Fujimura; Subbiah Yoganathan; Kimito Hirai; Shuang Xu; Kei Sasaki; Philip Stashenko
Journal:  J Endod       Date:  2019-02       Impact factor: 4.171

Review 3.  [Still's disease in children and adults].

Authors:  C M Hedrich; C Günther; M Aringer
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

4.  Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO).

Authors:  Sigrun Renate Hofmann; Anne Sophie Kubasch; Ursula Range; Martin Walther Laass; Henner Morbach; Hermann Joseph Girschick; Christian Michael Hedrich
Journal:  Rheumatol Int       Date:  2016-03-21       Impact factor: 2.631

Review 5.  New discoveries in CRMO: IL-1β, the neutrophil, and the microbiome implicated in disease pathogenesis in Pstpip2-deficient mice.

Authors:  Polly J Ferguson; Ronald M Laxer
Journal:  Semin Immunopathol       Date:  2015-04-17       Impact factor: 9.623

6.  Characteristics and outcomes of chronic non-bacterial osteitis in children.

Authors:  Stefanie Wintrich; Gerd Horneff
Journal:  Eur J Rheumatol       Date:  2015-08-21

Review 7.  Chronic non-bacterial osteomyelitis and autoinflammatory bone diseases.

Authors:  Yongdong Zhao; Polly J Ferguson
Journal:  Clin Immunol       Date:  2020-05-07       Impact factor: 3.969

Review 8.  Chronic Recurrent Multifocal Osteomyelitis and Related Diseases-Update on Pathogenesis.

Authors:  Allison J Cox; Yongdong Zhao; Polly J Ferguson
Journal:  Curr Rheumatol Rep       Date:  2017-04       Impact factor: 4.592

9.  Comparison of different treatment approaches of pediatric chronic non-bacterial osteomyelitis.

Authors:  Mikhail M Kostik; Olga L Kopchak; Irina A Chikova; Eugenia A Isupova; Alexander Y Mushkin
Journal:  Rheumatol Int       Date:  2018-08-31       Impact factor: 2.631

Review 10.  Autoinflammatory bone disorders: update on immunologic abnormalities and clues about possible triggers.

Authors:  Manisha Sharma; Polly J Ferguson
Journal:  Curr Opin Rheumatol       Date:  2013-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.